Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling

Objective: Lymphatic metastasis is one of the leading causes of malignancy dispersion in various types of cancer. However, few anti-lymphangiogenic drugs have been approved for clinical use to date. Therefore, new therapies to block lymphangiogenesis are urgently required. Methods: Immunohistochemis...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Tingting, Liu, Zhujun, Wang, Jing, Xia, Junling, Liu, Shaochuan, Jia, Yanan, Liu, Hailin, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476093/
https://www.ncbi.nlm.nih.gov/pubmed/32944404
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476093/
https://www.ncbi.nlm.nih.gov/pubmed/32944404
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0024

Ejemplares similares